Other formats:
BibTeX
LaTeX
RIS
@article{1386057,
author = {Matušková, Veronika and Balcar, Vladimír Josef and Khan, Naim A. and Bonczek, Ondřej and Ewerlingová, Laura and Zeman, Tomáš and Kolář, Petr and Vysloužilová, Daniela and Vlková, Eva and Šerý, Omar},
article_location = {Philadelphia},
article_number = {1},
doi = {http://dx.doi.org/10.1080/13816810.2017.1326508},
keywords = {Glaucoma; polymorphism; receptor; Schlemm´s canal; thrombospondin},
language = {eng},
issn = {1381-6810},
journal = {Ophthalmic Genetics},
title = {CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy},
url = {http://dx.doi.org/10.1080/13816810.2017.1326508},
volume = {39},
year = {2018}
}
TY - JOUR
ID - 1386057
AU - Matušková, Veronika - Balcar, Vladimír Josef - Khan, Naim A. - Bonczek, Ondřej - Ewerlingová, Laura - Zeman, Tomáš - Kolář, Petr - Vysloužilová, Daniela - Vlková, Eva - Šerý, Omar
PY - 2018
TI - CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy
JF - Ophthalmic Genetics
VL - 39
IS - 1
SP - 4-10
EP - 4-10
PB - Taylor & Francis
SN - 13816810
KW - Glaucoma
KW - polymorphism
KW - receptor
KW - Schlemm´s canal
KW - thrombospondin
UR - http://dx.doi.org/10.1080/13816810.2017.1326508
N2 - Background: The wet form of age-related macular degeneration (AMD) is characterized by pathological vascularization of the outer retinal layers. The condition responds to treatment with antibodies against vascular endothelial growth factor (VEGF), but the patients receiving such anti-VEGF therapy sometimes show undesirable acute short-term increases in the intraocular pressure (IOP). The cause of this adverse effect is unknown, and here, we are testing a hypothesis that it is related to CD36 gene polymorphisms. Materials and Methods: A group of 134 patients with AMD were given three therapeutic doses of anti-VEGF antibody (ranibizumab) at monthly intervals. Their IOP was measured immediately before and 30 min after each injection. Patients’ DNA was analyzed, and the changes in IOP were matched against seven polymorphisms of the CD36 gene. Results: Three polymorphisms were found to be associated with increases in IOP: rs1049673 (p = 0.006), rs3211931 (p = 0.01), and rs1761667 (p = 0.043) at the time of the third injection only. Pronounced elevations (IOP > 25 mmHg) were associated with rs1049673 polymorphism: GC genotype (p < 0.01) and CC genotype (p < 0.05); both increasing the risk 2.6-fold, the presence of C-allele conferring a 1.5-fold greater risk and with rs3211931 polymorphism: AG genotype (p < 0.01) and GG genotype (p < 0.05); increasing the risk 2.6-fold (AG) and 2.7-fold (GG). Conclusions: CD36 receptor may be involved in mediating the effects of VEGF on IOP. The findings will help to identify the patients at risk of acutely elevated IOP following the anti-VEGF therapy.
ER -
MATUŠKOVÁ, Veronika, Vladimír Josef BALCAR, Naim A. KHAN, Ondřej BONCZEK, Laura EWERLINGOVÁ, Tomáš ZEMAN, Petr KOLÁŘ, Daniela VYSLOUŽILOVÁ, Eva VLKOVÁ and Omar ŠERÝ. CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy. \textit{Ophthalmic Genetics}. Philadelphia: Taylor \&{} Francis, 2018, vol.~39, No~1, p.~4-10. ISSN~1381-6810. Available from: https://dx.doi.org/10.1080/13816810.2017.1326508.
|
